Newsletter Subject

Discover the Future of Cancer Vaccines at SITC 2024!

From

primeinc.org

Email Address

cme@email.primeinc.org

Sent On

Wed, Sep 18, 2024 09:36 PM

Email Preheader Text

Join leading experts to explore advances in immuno-modulating cancer vaccines and their potential to

Join leading experts to explore advances in immuno-modulating cancer vaccines and their potential to transform cancer care. [PRIME]( [Harnessing the Power of Immuno-Modulating Vaccines in Cancer Treatment]( [REGISTER NOW!]( [Event Details:]( [Houston, TX Friday, Nov 8, 2024 at 5:30 PM Central]([George R. Brown Convention Center Room 310 C 1001 Avenida de las Americas Houston, Texas 77010 (713) 853-8000]( [Attend Virtually: 1.0 CME/CE | Live Event / Live Webinar]( Join us for this dynamic live satellite symposium offered in conjunction with the Society for Immunotherapy of Cancer (SITC) 2024 meeting as two esteemed oncologists examine groundbreaking treatment advances in cancer vaccines, focusing on emerging evidence and mechanisms of action behind novel immune-modulating therapeutic cancer vaccines, including recent clinical data in advanced melanoma. Discover how these innovative treatments are poised to transform the treatment paradigm, offering new options for patients with cancer. Hear expert insights on clinical implications of emerging evidence, including patient eligibility, treatment selection, and considerations for integration of novel cancer vaccines into clinical practice. Don't miss this unique opportunity to get your most pressing questions answered by leading experts and explore the potential of these novel treatment approaches to improve health outcomes for patients with advanced melanoma and other cancers. Expert Faculty: Jason J Luke, MD, FACP Speaker Associate Director of Clinical Research Director - Immunotherapy and Drug Development Center UPMC Hillman Cancer Center Associate Professor of Medicine Division of Hematology/Oncology University of Pittsburgh School of Medicine Pittsburgh, PA Ryan J Atkinson, PharmD, MBA Speaker Senior Director, Payer Relations PANTHERx Rare Pharmacy Indianapolis, IN [REGISTER NOW!]( [Prime Education] PRIME Education, LLC 114 5th Ave, 14th Floor New York, NY 10011 (954) 718-6055 | [Contact us]( PRIME is a multi-disciplinary accredited provider of continuing medical education. [Unsubscribe from future emails](lst=NL_Prime_Live_Events) | [Contact us]( | [COVID-19 Resource Center](

Marketing emails from primeinc.org

View More
Sent On

07/11/2024

Sent On

05/11/2024

Sent On

05/11/2024

Sent On

29/10/2024

Sent On

28/10/2024

Sent On

25/10/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.